DelSiTech Ltd., a company specializing in clinical-stage drug delivery and development, has announced a global license and development agreement with Tolmar International Ltd., a fully-integrated pharmaceutical company. This agreement strengthens their collaboration, which began with Tolmar's investment in January 2024.

According to the agreement, Tolmar will gain a worldwide license to utilize DelSiTech's proprietary silica-based drug delivery technology platform for the development and commercialization of two undisclosed long-acting injectable drug products. Additionally, both companies will collaborate to explore further development opportunities in various therapeutic areas, such as urology, reproductive health, and pediatric endocrinology, using controlled release drug products based on Silica Matrix.

While specific financial details were not disclosed, DelSiTech will receive upfront payment, development and commercial milestone payments, and royalties on the net sales of licensed products as part of the agreement.

DelSiTech, expressed excitement about expanding the partnership with Tolmar, emphasizing the potential of their proprietary drug delivery technology platform to develop novel products for patients in need of improved therapies.

Tolmar, also highlighted the significance of the partnership, stating that it could strengthen Tolmar's position as a leader in long-acting injectable drug products and enhance their portfolio for the benefit of patients.

 

Source: prnewswire.com

Report Abuse